Profile picture

Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)
Follow
Biography
Christopher P. Cannon, MD Cardiovascular Innovation, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School, Boston, MA Remote faculty, Clinician-Scientist, CPC Clinical Research Institute Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He serves as Education Director in the Cardiovascular Innovation group, and has recently joined the remote faculty as a Clinician Scientist at the CPC Clinical Research Institute. In the past, he has worked as an investigator in the TIMI Study Group. He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS-CV trials. At Cardiovascular Innovation, he is helping implement quality improvement programs using telemedicine for lipids, hypertension and diabetes, and at CPC Clinical Research as he is helping lead pragmatic clinical trials.
Logo ESC

Contributor content

Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic
Session
Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic
2 September 2019
NOACs in patients undergoing cardiac procedures
Session
NOACs in patients undergoing cardiac procedures
2 September 2019
Meet the trialist - ASCEND - Randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes & Randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes
Session
Meet the trialist - ASCEND - Randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes & Randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes
27 August 2018
Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
Session
Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
26 August 2018
Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent percutaneous coronary intervention
Session
Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent percutaneous coronary intervention
26 August 2018
ESC ATLAS of Cardiology: statistics on cardiovascular disease and care
Session
ESC ATLAS of Cardiology: statistics on cardiovascular disease and care
25 August 2018
PSCK9 inhibition: a new horizon in LDL-C management
Session
PSCK9 inhibition: a new horizon in LDL-C management
28 August 2017
Antithrombotic strategies post-PCI in atrial fibrillation: new insights, new approach
Session
Antithrombotic strategies post-PCI in atrial fibrillation: new insights, new approach
28 August 2017
RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation
Session
RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation
28 August 2017
Predicting and preventing acute events in patients with stable coronary artery disease
Session
Predicting and preventing acute events in patients with stable coronary artery disease
28 August 2017

ESC 365 is supported by